{
    "clinical_study": {
        "@rank": "159621", 
        "arm_group": [
            {
                "arm_group_label": "azithromycin 1.5%/Loteprednol 0,5% + placebo", 
                "arm_group_type": "Experimental", 
                "description": "fixed combination of azithromycin 1.5% / Loteprednol 0,5% eye drops + placebo eye drops"
            }, 
            {
                "arm_group_label": "azithromycin 1.5% + Loteprednol 0,5% (separately)", 
                "arm_group_type": "Active Comparator", 
                "description": "azithromycin 1.5% + Loteprednol 0,5% eye drops (separately)"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and safety of fixed combination of azithromycin 1.5% + 0.5%\n      Loteprednol eye drops for the treatment of ocular inflammation and infection associated\n      bacterial blepharitis and / or keratitis and / or conjunctivitis compared with the\n      individual administration of azithromycin 1.5% and 0.5% Loteprednol (separately)."
        }, 
        "brief_title": "Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ocular Inflammation", 
            "Infection Associated Blepharitis", 
            "Keratitis", 
            "Conjunctivitis, Bacterial"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Blepharitis", 
                "Conjunctivitis", 
                "Conjunctivitis, Bacterial", 
                "Inflammation", 
                "Keratitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Estimated to be admitted a total of approximately 60 patients  showing blepharitis and / or\n      keratitis and / or conjunctivitis: 30 patients will be assigned to the group of Azithromycin\n      1.5%/Loteprednol 0.5% Eye Drops (fixed combination) + placebo and 30 patients will be\n      assigned to the group of Azithromycin 1.5% + 0.5% Loteprednol (separately)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients were male or female, of any race and age minimum of 18 years.\n\n          -  Blepharitis should provide diagnostic and / or keratitis and / or conjunctivitis with\n             or without bacterial involvement corneal by biomicroscopy, with positive staining\n             corneal fluorescein and also provide a composite score \u2265 2 on: bulbar conjunctival\n             hyperemia, eyelid conjunctiva, secretion / exudate conjunctival erythema and flaking\n             eyelids / eyelid crust on at least one eye (the same eye) on Day 1 visit\n\n        Exclusion Criteria:\n\n          -  Intraocular hypertension or uncontrolled glaucoma.\n\n          -  Use of contact lenses during the study.\n\n          -  Capacity unilateral visual only.\n\n          -  Suspected fungal infection, viral (eg, herpes simplex epithelial, dendritic\n             keratitis) or Acanthamoeba, or any other disease where the use of corticosteroids is\n             contraindicated.\n\n          -  Use of any topical ophthalmic medications preserved during study participation. Not\n             be allowed eyedrops preserved (eg artificial tears).\n\n          -  Use of any antibacterial agent oral or topical ophthalmic until 72 hours prior to\n             study entry.\n\n          -  Use of systemic steroids within 14 days prior to study entry. Ophthalmic topical\n             steroids or nonsteroidal anti-inflammatory drugs (NSAIDs), until one week before\n             admission to the study. Will not be allowed to use these medications during study\n             participation. Will not be allowed to use nasal steroids during the study. Will be\n             allowed to use inhaled steroids to aid inhaler. Will be allowed steroids dermal\n             topics.\n\n          -  Use of nonsteroidal anti-inflammatory drugs (NSAIDs) systemic up to 24 hours prior to\n             study entry or at any time during the study, unless the patient is under treatment\n             regimen with stable (not necessary) for at least 2 months before Admission and\n             therapy continues throughout the study.\n\n          -  Any disturbance or ocular or systemic disease, complicating factors or structural\n             abnormality that affects the conduct or outcome of the study in a negative way or\n             represents an undue risk to patient safety, according to the opinion of the\n             investigator.\n\n          -  Any current immunosuppressive disorder (eg, HIV-positive), or immunosuppressive\n             therapy (including chemotherapy).\n\n          -  Known allergy or suspected allergy or hypersensitivity to fluoroquinolones, to\n             steroids or any other component of the study drug;\n\n          -  Pregnant or lactating. (Women of childbearing age may be admitted if they use\n             contraception and submit urine pregnancy test negative);\n\n          -  Any patient who has a family member who participates in this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01721694", 
            "org_study_id": "AZILOT-12", 
            "secondary_id": "131.835"
        }, 
        "intervention": [
            {
                "arm_group_label": "azithromycin 1.5%/Loteprednol 0,5% + placebo", 
                "description": "1 drop, AO, QID", 
                "intervention_name": "azithromycin 1.5%/Loteprednol 0,5% + placebo", 
                "intervention_type": "Drug", 
                "other_name": "azithromycin 1.5%/Loteprednol 0,5% + placebo"
            }, 
            {
                "arm_group_label": "azithromycin 1.5% + Loteprednol 0,5% (separately)", 
                "description": "1 drop, QID, AO", 
                "intervention_name": "azithromycin 1.5% + Loteprednol 0,5% (separately)", 
                "intervention_type": "Drug", 
                "other_name": "azithromycin 1.5% + Loteprednol 0,5% eye drops (separately)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tetrahydrozoline", 
                "Azithromycin", 
                "Loteprednol etabonate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "bacterial ocular inflammation", 
            "blepharitis", 
            "keratitis", 
            "conjunctivitis"
        ], 
        "lastchanged_date": "November 5, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "S\u00e3o Paulo", 
                    "country": "Brazil", 
                    "zip": "04023-062"
                }, 
                "name": "Department of Ophthalmology of Hospital S\u00e3o Paulo"
            }, 
            "investigator": [
                {
                    "last_name": "Rubens Belfort, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Cristina Muccioli, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Association of Azithromycin 1,5%/Loteprednol 0,5% Eye Drops Versus Individual Administration of Azithromycin 1,5% and Loteprednol 0,5% in the Treatment of Ocular Inflammation and Infection", 
        "other_outcome": {
            "description": "decrease of visual acuity, corneal/anterior chamber changes, IOP increase and adverse event reporting", 
            "measure": "ophthalmic evaluation", 
            "safety_issue": "Yes", 
            "time_frame": "Day 4 and Day 8"
        }, 
        "overall_contact": {
            "email": "crissmucci@gmail.com", 
            "last_name": "Cristina Muccioli, MD", 
            "phone": "5511-99748809"
        }, 
        "overall_contact_backup": {
            "email": "luci.pesquisa@gmail.com", 
            "last_name": "Luci Silva, MBA", 
            "phone": "5511-71571967"
        }, 
        "overall_official": {
            "affiliation": "Federal University of S\u00e3o Paulo / Hospital S\u00e3o Paulo", 
            "last_name": "Rubens Belfort Jr., MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Health Surveillance Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clinical cure achieved when the score of the cardinal ocular signs (hyperemia in the bulbar conjunctiva, palpebral, exudate / conjunctival discharge, eyelid erythema and flaking / crust eyelid) is zero at the time of conclusion of the study (D8)", 
            "measure": "Clinical cure", 
            "safety_issue": "No", 
            "time_frame": "Day 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01721694"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Success obtained with microbiological irradication of pathogens present at baseline", 
            "measure": "irradication of pathogens", 
            "safety_issue": "No", 
            "time_frame": "Day 8"
        }, 
        "source": "Adapt Produtos Oftalmol\u00f3gicos Ltda.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Adapt Produtos Oftalmol\u00f3gicos Ltda.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}